key: cord-0895911-vbs937sr
authors: Khalil, A.; Samara, A.; Chowdhury, T.; O'Brien, P.
title: Does COVID‐19 cause pre‐eclampsia?
date: 2021-11-11
journal: Ultrasound Obstet Gynecol
DOI: 10.1002/uog.24809
sha: a059dff3d2604f72525168c8c2e13dade3ba7fb1
doc_id: 895911
cord_uid: vbs937sr

nan

The Coronavirus Disease 2019 (COVID-19) pandemic has had a significant impact on the provision of maternal healthcare and maternal and fetal outcomes globally [1] [2] [3] [4] . An increase in maternal morbidity and mortality has been identified and has been attributed to a number of causes 5 . These include difficulties faced by healthcare systems in adapting to rapidly changing circumstances during the pandemic and inequity in service provision globally according to income status of countries 6 .

In general, women are at increased risk of infection during pregnancy. Alterations in immune function and increased physiological demand on maternal metabolism can lead to more complicated recovery and worse outcomes 7 . In particular, pregnant women are at increased risk of severe respiratory illness, for example, influenza 8, 9 . During the COVID-19 pandemic, the relationship between severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and maternal health has been explored in a number of large-scale cohort studies and meta-analyses of the current literature. These studies have highlighted an apparent link between COVID-19 and preeclampsia [10] [11] [12] , but it is not currently known whether or not this association is causal.

In 1965, the English statistician Sir Austin Bradford Hill proposed a set of nine criteria to assess causality in the relationship between a presumed cause and an observed effect 13 . While some argue against the exclusive use of these criteria to judge causality, arguing for example that scientific deduction is more powerful, they are still widely accepted and applied. These criteria are: the strength of the association (effect size), consistency (reproducibility), specificity, temporal sequence, biological gradient (dose-response relationship), plausibility, coherence (between epidemiological and laboratory findings), experimental evidence, and analogous evidence. Some authors include reversibility, i.e., if the cause is removed, the effect should disappear too. We assessed the relationship between SARS-CoV-2 infection in pregnancy and the development of preeclampsia against the Bradford Hill criteria.

(The larger the association, the greater the likelihood that the relationship is causal).

A large-scale national cohort study of 342,090 women was conducted in England between 29 th May 2020 and 31 st July 2021 as part of the National Maternity and Perinatal Audit (NMPA) 14 . This study found that women testing positive for SARS-CoV-2 at the time of birth had higher rates of fetal death, preterm delivery, preeclampsia and delivery by emergency cesarean section, compared with women without a positive test for SARS-CoV-2. The risk of preeclampsia or eclampsia was significantly higher for women with SARS-CoV-2 infection than those without ( Several large cohort studies that highlighted important outcomes such as increased maternal morbidity in UK and US populations, including the PANCOVID (UK) and AAP-SONPM (US) registry study 16, 17 , were not designed specifically to assess the incidence of preeclampsia or other hypertensive disorders of pregnancy, so unfortunately did not add any data useful for addressing this question.

A recent systematic review and meta-analysis by Conde-Agudelo and Romero 12 included a total of 28 studies including 790,954 pregnant women. Of these 28 studies, 14 were conducted in North America, 6 in Europe, 5 in Asia, and 2 in Latin America. The remaining study was performed across 18 countries. This meta-analysis assessed heterogeneity among studies by visually inspecting forest plots and by estimating I 2 . Significant heterogeneity was pre-defined as an I 2 value ≥ 30%. The pre-specified subgroups analysed to explore potential sources of This analysis found that the direction and magnitude of the effect of SARS-CoV-2 infection during pregnancy on preeclampsia was consistent across most pre-specified subgroup and sensitivity analyses. However, smaller studies (<200 women), those with a retrospective design that did not adjust for confounding factors, and studies from Asia, reported slightly higher ORs than larger, cross-sectional studies that did adjust for confounding factors.

It should be recognised that this meta-analysis was dominated by two large cross-sectional studies, one from the UK 14 , the other from the US 18 , which between them contributed 748,526 (94.6%) of the 790,954 pregnant women included in this meta-analysis, which could potentially temper the conclusions drawn around reproducibility in different countries and ethnicities.

However, this UK study 14 , which included White (76.3%), Asian (12.2%) and Black (4.6%) pregnant women, found that the association between SARS-CoV-2 and preeclampsia persisted even after multiple regression adjusting for maternal age, ethnicity, parity, preexisting diabetes mellitus, pre-existing hypertension, and socioeconomic deprivation measured using Index of Multiple Deprivation 2019 (IMD).

The INTERCOVID study 20 found that women who were overweight at the first antenatal visit and were subsequently diagnosed with COVID-19 had the highest risk of preeclampsia/eclampsia (RR, 2.62; 95% CI, 1.57-4.36), suggesting that being overweight modifies the effect of COVID-19 exposure.

In summary, there is good evidence around the consistency of this association, but further evidence is needed.

(Causation is likely if there is a very specific population at a specific site and disease with no other likely explanation).

Preeclampsia is a disease specific to pregnancy. The risk factors for the development of preeclampsia are well-documented and include hypertensive disease in previous pregnancy, chronic hypertension, chronic renal disease, diabetes mellitus or autoimmune disease, nulliparity, age ≥40 years, raised BMI ≥35 kg/m 2 , family history of preeclampsia, interpregnancy interval >10 years, or conception by in-vitro fertilization 21, 22 . Low dose aspirin, started before 15 weeks' gestation, reduces the risk of preeclampsia 23 .

It is not clear whether pregnant women are at increased risk of contracting SARS-CoV-2 infection, but the risk factors for developing more severe COVID-19 in pregnancy are similar to those in non-pregnant individuals, namely Black, Asian or minority ethnicity, overweight/obesity, or chronic co-morbidity (in particular asthma and hypertension) 19 . The overlap in risk factors for preeclampsia and severe COVID-19 highlight the potential for confounding in the association between the two conditions. The 28 studies included in the Conde-Agudelo and Romero meta-analysis 12 varied significantly in the maternal factors for which they adjusted, but most adjusted for maternal age, BMI, pre-existing comorbidities, and race/ethnicity. Fourteen studies did not adjust for any confounders or perform any matching of variables. Four studies were designed specifically to evaluate the association between SARS-CoV-2 infection during pregnancy and preeclampsia 15, [24] [25] [26] [27] . Of these, one 24 did not adjust for any confounding factors; one 25 adjusted for race and parity, one 26 adjusted for race, BMI, the use of low dose aspirin, and chronic hypertension; and one 15 factors for preeclampsia has been incomplete at best, but these results suggest that the relationship between SARS-CoV-2 infection in pregnancy and subsequent preeclampsia is maintained even after adjustment for some of these potential confounding factors.

The systematic review by Conde-Agudelo and Romero 12 In the absence of prospective cohort studies of women with and without a diagnosis of SARS-CoV-2 infection evaluating the subsequent development of preeclampsia, there is likely to be significant under-reporting of women who had this infection but did not go on to develop preeclampsia. In most women included in the current studies, the diagnosis of SARS-CoV-2 infection was made in the third trimester; given that the origins of the pathophysiology of preeclampsia are thought to arise in the first and early second trimesters, it might be expected that any causal relationship would be more readily established with SARS-CoV-2 infection at those earlier gestations.

In conclusion, the temporal relationship between pre-eclampsia has been suggested by these studies but has not been confirmed.

(Greater exposure should generally lead to greater incidence of the effect).

In the systematic review by Conde-Agudelo and Romero 12 both asymptomatic and symptomatic SARS-CoV-2 infection significantly increased the odds of preeclampsia.

However, this association was stronger for patients with symptomatic illness (OR 2.11, 95% CI 1.59-2.81) than for those with asymptomatic infection (OR 1.59, 95% CI 1.21-2.10).

A meta-analysis 28 The INTERCOVID study reported that longer duration of symptomatic COVID-19 was associated with increased relative risk of preeclampsia, eclampsia or HELLP syndrome 15 .

A retrospective observational study 27 of 1,223 pregnant women in the UK compared the severity of SARS-CoV-2 infection in pregnancy and the likelihood of subsequent preeclampsia. Patients were classified into four groups according to disease severity based on NIH criteria: asymptomatic, mild, moderate and severe. The model included adjustment for the prior risk of preeclampsia based on maternal characteristics and medical history, using a competing risk model. Women in whom the diagnosis of preeclampsia was made before the diagnosis of SARS-CoV-2 infection were excluded from the analysis. Compared with a background (expected) risk of preeclampsia of around 1%, the observed incidence of preeclampsia in those with asymptomatic, mild, moderate and severe SARS-CoV-2 infection was 1.9%, 2.2%, 5.7%, and 11.1%, respectively. This monotonic relationship was statistically significant (chi-square test for trend; p=0.0017). After adjusting for differences in the prior risk of preeclampsia as determined by the competing risk model, severe COVID-19 disease was associated with an almost 5-fold higher risk of preeclampsia than was asymptomatic infection (aRR=4.9; 95% CI 1.56-15.38). Moderate or severe COVID-19 was also associated with a greater risk of preeclampsia compared to those with asymptomatic or mild infection (aRR= 3.3; 95% CI 1. 48-7.38) . The authors argued that their finding that the more severe the SARS-CoV-2 infection, the greater the risk of preeclampsia, supports the hypothesis of a causal relationship.

(A plausible mechanism between cause and effect). There are, therefore, several plausible mechanisms by which SARS-CoV-2 infection could lead to the development of preeclampsia.

The laboratory evidence cited above that demonstrates downregulation of ACE2, increased production of antiangiogenic factors, nitric oxide modulators and prothrombotic molecules by SARS-CoV-2 is consistent with the epidemiological data. 

One meta-analysis identified a higher incidence of preeclampsia in pregnant women with coronavirus spectrum infections (including severe acute respiratory syndrome (SARS), Middle East Respiratory Syndrome (MERS) and COVID-19) than in the general pregnant population 11 .

If SARS-CoV-2 infection can cause preeclampsia, then vaccination against COVID-19, antiviral therapies, and COVID-19 pandemic mitigation measures would be expected to reduce the risk of preeclampsia. One preprint study 47 compared pregnancy outcomes between women vaccinated or unvaccinated against COVID-19. Vaccination protected against SARS-CoV-2 infection prior to delivery (1.4% vs 11.3%; RR 0.13, 95% CI 0.03-0.50; P=0.003), and was also associated with a non-significant decrease in the incidence of preeclampsia (0.7% vs 1.2%; RR 0.58, 95% CI 0.08-4.25; P=0.59). Ongoing randomized placebo-controlled trials of COVID-19 vaccination in pregnancy will establish whether vaccination reduces the risk of SARS-CoV-2 infection and adverse pregnancy outcomes, including preeclampsia.

Even though the currently available evidence would support the proposed hypothesis that COVID-19 could potentially cause preeclampsia, there are several limitations, and more research is needed to address the remaining questions before this assertion is made. The reported association of approximately 1.5 (compared to strength of association of a 200-fold increase in cancer in chimney sweepers used by Bradford Hill), would be considered as too small for a proven causal link and would more conceivably be attributed to other underlying contributors (i.e. bias or confounding). Moreover, the Bradford Hill's criteria have been questioned following the advancements in genetics, exposure science and statistics in the 21st century 48 . These advancements have improved our analytical capabilities for exploring potential cause-and-effect relationships and our ability to appreciate the complexity of onset and progression of diseases. These advancements in science and our understanding of disease origin had led some researchers to question the Bradford Hill's criteria when considering multifactorial causality 48 .

There is growing evidence that the association between SARS-CoV-2 infection in pregnancy and preeclampsia is causal, particularly in relation to the biological gradient and plausibility.

Clearly, however, more evidence is needed to bolster the other criteria, particularly in relation to temporal sequence, which is perhaps the only criterion which epidemiologists universally agree is essential to causal inference 48 . It is possible that a causal link is mediated through placental or cardiovascular pathology, but further studies are required to understand these potential mechanisms.

Since the Bradford Hill criteria for helping to determine whether observed epidemiological associations are causal were published in 1965, there have been seismic advances in a range of scientific fields (e.g., molecular genetics, genomics, molecular toxicology, genotoxicology) and technology (e.g., computers, software, statistics, analytical methods). These disciplines can be used to 'peer into the black box' (as it was known at the time) between exposure and disease 48 . This means that the cause-effect relationship can often be established with a degree of certainty, leading some to argue that in these instances, reliance on the Bradford Hill criteria becomes less relevant. Others, however, argue that data integration can enhance the application of the Bradford Hill Criteria in a causal analysis by integrating new techniques into each of the criteria, making conclusions about causality more robust 48 . It must also be acknowledged that in the case of SARS-CoV-2 infection and preeclampsia, we are still just beginning to shine some light into this particular 'black box' between exposure and disease.

Healthcare professionals should be aware that SARS-CoV-2 infection in pregnant women, even in those who remain asymptomatic, is a risk factor for the subsequent development of preeclampsia. They should also be cognisant of the additive effect of the combination of these two conditions on adverse pregnancy outcomes. Pregnant women who test positive for SARS-CoV-2 will benefit from close monitoring of blood pressure, liver and renal function to allow early diagnosis of preeclampsia and HELLP syndrome 49 . It may also be useful for women presenting with preeclampsia but non-classical biochemical markers to have a SARS-CoV-2 PCR swab (where testing on admission is not universal) 49 .

Effect of the COVID-19 pandemic response on intrapartum care, stillbirth, and neonatal mortality outcomes in Nepal: a prospective observational study

COVID-19 outbreak and decreased hospitalisation of pregnant women in labour

Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial

Authors' reply re: Maternity services in the UK during the coronavirus disease 2019 pandemic: a national survey of modifications to standard care

Effects of the COVID-19 pandemic on maternal and perinatal outcomes: a systematic review and meta-analysis

The impact of the COVID-19 pandemic on maternal and perinatal health: a scoping review. Reprod Health

Changes in physiology and immune system during pregnancy and coronavirus infection: A review

Incidence, risk factors and impact of seasonal influenza in pregnancy: A national cohort study

Incidence of influenza during pregnancy and association with pregnancy and perinatal outcomes in three middle-income countries: a multisite prospective longitudinal cohort study

Maternal and Neonatal Morbidity and Mortality Among Pregnant Women With and Without COVID-19 Infection: The INTERCOVID Multinational Cohort Study

Outcome of coronavirus spectrum infections (SARS, MERS, COVID-19) during pregnancy: a systematic review and meta-analysis

SARS-COV-2 infection during pregnancy and risk of preeclampsia: a systematic review and meta-analysis

The environment and disease: association or causation?

Maternal and perinatal outcomes of pregnant women with SARS-CoV-2 infection at the time of birth in England: national cohort study

Papageorghiou AT. Maternal and Neonatal Morbidity and Mortality Among Pregnant Women With and Without COVID-19 Infection: The INTERCOVID Multinational Cohort Study

Multisociety Consensus Quality Improvement Revised Consensus Statement for Endovascular Therapy of Acute Ischemic Stroke

Pregnancy and neonatal outcomes of COVID-19: coreporting of common outcomes from PAN-COVID and AAP-SONPM registries

Clinical characteristics and outcomes of hospitalized women giving birth with and without COVID-19

Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and metaanalysis

Preeclampsia and COVID-19: results from the INTERCOVID prospective longitudinal Study

Hypertension in Pregnancy: The Management of Hypertensive Disorders During Pregnancy

First-trimester risk assessment for early-onset preeclampsia

Aspirin versus Placebo in Pregnancies at High Risk for Preterm Preeclampsia

COVID-19 and new hypertensive disease in pregnancy

Coronavirus disease 2019 infection and hypertensive disorders of pregnancy

Incidence of hypertensive disorders of pregnancy in women with COVID-19

SARS-COV-2 and the subsequent development of preeclampsia and preterm birth: evidence of a dose response relationship supporting causality

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Maternal

Disease Severity and Perinatal Outcomes of Pregnant Patients With Coronavirus Disease 2019 (COVID-19)

Is COVID-19 a risk factor for severe preeclampsia? Hospital experience in a developing country

Angiotensin-Converting Enzyme 2: SARS-CoV-2 Receptor and Regulator of the Renin-Angiotensin System: Celebrating the 20th Anniversary of the Discovery of ACE2

A historical perspective on ACE2 in the COVID-19 era

Commentary: SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Front Oncol

SARS-CoV-2 can infect the placenta and is not associated with specific placental histopathology: a series of 19 placentas from COVID-19-positive mothers

COVID-19 infection: ACE2, pregnancy and preeclampsia

Expression of severe acute respiratory syndrome coronavirus 2 cell entry genes, angiotensin converting enzyme 2 and transmembrane protease serine 2, in the placenta across gestation and at the maternalfetal interface in pregnancies complicated by preterm birth or preeclampsia

Term human placental trophoblasts express SARS-CoV-2 entry factors ACE2, TMPRSS2, and Furin

Consistent localization of SARS-CoV-2 spike glycoprotein and ACE2 over TMPRSS2 predominance in placental villi of 15 COVID-19 positive maternal-fetal dyads

SARS-CoV-2 infects syncytiotrophoblast and activates inflammatory responses in the placenta

SARS-CoV-2 colonization of maternal and fetal cells of the human placenta promotes alteration of local renin-angiotensin system

Preeclampsia: Pathophysiology, Challenges, and Perspectives

The risk of COVID-19 for pregnant women: evidences of molecular alterations associated with preeclampsia in SARS-CoV-2 infection

Placental Pathology of Zika Virus: Viral Infection of the Placenta Induces Villous Stromal Macrophage (Hofbauer Cell) Proliferation and Hyperplasia

Recent Updates on Research Models and Tools to Study Virus-Host Interactions at the Placenta. Viruses

Placental Pathology in COVID-19

Placental Pathology Findings during and after SARS-CoV-2 Infection: Features of Villitis and Malperfusion

SARS-CoV-2 placentitis: An uncommon complication of maternal COVID-19

Pregnancy and birth outcomes after SARS-CoV-2 vaccination in pregnancy. medRxiv

Applying the Bradford Hill criteria in the 21st century: how data integration has changed causal inference in molecular epidemiology

Severe pre-eclampsia complicated by acute fatty liver disease of pregnancy, HELLP syndrome and acute kidney injury following SARS-CoV-2 infection

Mechanism of preeclampsia in COVID-19